Pharmacologically active natural compounds for lung cancer

Alternative Medicine Review

Volumn 9, Issue 4, 2004, Pages 402-419

  Ancuceanu, Robert Viorel ^a,b   Istudor, Viorica ^c  

^a Dept of the Pharmaceutical Botany ^*  (Romania)

^b Romanian Ministry of Health   (United Kingdom)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

8 EPIXANTHIN; ALKYLATING AGENT; ANNONACIN; ANTOFINE; BAICALEIN; BRUCEANTIN; BULLATACIN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; GIGANTETROCIN A; GIGANTETROCIN B; LIPOXYGENASE INHIBITOR; LYCOBETAINE; METHYL ROCAGLATE; MONTANACIN C; NATURAL PRODUCT; PACLITAXEL; PRETAZETTINE; PROTEIN SYNTHESIS INHIBITOR; QUASSINOID; RESVERATROL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSOLIC ACID; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; WOGONIN;

AGLAIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CAMPTOTHECA; CANCER CELL CULTURE; CEPHALOTAXUS; CHEMICAL COMPOSITION; CONTROLLED STUDY; CYNANCHUM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG CANCER; LYCORIS; MOUSE; NONHUMAN; REVIEW; SCUTELLARIA BAICALENSIS; SYSTEMATIC REVIEW; VISCUM ALBUM; XANTHIUM; ZANTHOXYLUM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; LUNG NEOPLASMS; PHYTOTHERAPY;

EID: 11244313152     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. World Health Organization. GLOBOCAN 2000: Cancer Incidence. Mortality and Prevalence Worldwide. Version 1.0. IARC CancerBase No. 5. Lyon, IARCPress: 2001. http://www-dep.iarc.fr/slobocan/globocan.html [23.08.2004]
2. American Cancer Society. Cancer Facts & Figures; 2004. http://www.cancer.org [23.08.2004]
3. Strassheim D, Shafer SH, Phelps SH, Williams CL. Small cell lung carcinoma exhibits greater phospholipase c-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res 2000;60:2730-2736.
4. Clegg A, Scott DA, Hewitson P, et al. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 2002;57:20-28.
5. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-67.
6. Chan D, Gera L, Stewart J, et al. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc Natl Acad Sci USA 2002;99:4608-4613.
7. Young LC, Campling BG, Cob SP, et al. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001;7:1798-1804.
8. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-1210.
9. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S-49S.
10. Frei E 3rd. Non-small cell lung cancer. Novel treatment strategies. Chest 1997;112:2665-268S.
11. Bunn PA Jr, Kelly K. New combinations in the treatment of lung cancer: a time for optimism. Chest 2000;117:138S-143S.
12. Fukuoka M. State of the art of non-small-cell lung cancer in the new millennium. Oncology (Huntingt) 2001;15:9-11.
13. Johnson DH. Locally advanced, unresectable non-small cell lung cancer: new treatment strategies. Chest 2000;117:123S-126S.
14. Brahmer JR, Ettinger DS. The role of topotecan in the treatment of small cell lung cancer. Oncologist 1998;3:11-14.
15. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61:3-13.
16. Sandler A. Irinotecan therapy for small-cell lung cancer. Oncology (Huntingt) 2002;16:419-425,428,433.
17. Ettinger DS, Finkelstein DM, Ritch PS, et al. Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer 2002;37:311-318.
18. Dowlati A, Crosby L, Remick SC, et al. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer - the use of complete response rate as the primary endpoint in phase II trials. Lung Cancer 2001;32:155-162.
19. Shan B, Medina JC, Santha E, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vitro efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A 1999;96:5686-5691.
20. Banan A, Choudhary S, Zhang Y, et al. Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. J Pharmacol Exp Ther 1999;291:1075-1085.
21. Kim YS, Kim JS, Park SH, et al. Two cytotoxic sesquiterpene lactones from the leaves of Xanthium strumarium and their in vitro inhibitory activity on farnesyltransferase. Planta Med 2003;69:375-377.
22. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:1760-1766.
23. Menon GS, Kuchroo K, Dasgupta D. Interaction of microtubules with active principles of Xanthium strumarium. Physiol Chem Phys Med NMR 2001;33:153-162.
24. Eckardt J, Eckhardt G, Villalona-Calero M, et al. New anticancer agents in clinical development. Oncology (Huntingt) 1995;9(Part 1):1191-1199, 9(Part 2): 1321-1337.
25. Eckardt J, Eckhardt G, Villalona-Calero M, et al. New anticancer agents in clinical development. Oncology (Huntingt) 1995;9(Part 1):1191-1199, 9(Part 2): 1321-1337.
26. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995;270:21429-21432.
27. Berger JM, Fass D, Wang JC, Harrison SC. Structural similarities between topoisomerases that cleave one or both DNA strands. Proc Natl Acad Sci U S A 1998;95:7876-7881.
28. This short overview of topoisomerases is the result of personal research, a synthesis of the relevant literature on the biological significance of topoisomerases in the treatment of cancer; to be published soon.
29. Tang W, Hemm I, Bertram B. Recent development of antitumor agents from Chinese herbal medicines; part I. Low molecular compounds. Planta Med 2003;69:97-108.
30. Barthelmes HU, Niederberger E, Roth T, et al. Lycobetaine acts as a selective topoisomerase II beta poison and inhibits the growth of human tumour cells. Br J Cancer 2001;85:1585-1591.
31. Wang P, Shi GB, Song GQ, et al. Assignment of proton resonances and conformational characterization of oligodeoxyribonucleic acid d(CCGTACGG) in solution. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 1996;28:703-705.
32. Liu J, Yang SL, Xu B. Characteristics of the interaction of lycobetaine with DNA. Zhongguo Yao Li Xue Bao 1989;10:437-442.
33. Fleury F, Sukhanova A, Ianoul A, et al. Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine. Relation to DNA binding. J Biol Chem 2000;275:3501-3509.
34. Wang LK, Johnson RK, Hecht SM. Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol 1993;6:813-818.
35. Gakunju DM, Mberu EK, Dossaji SF, et al. Potent antimalarial activity of the alkaloid nitidine, isolated from a Kenyan herbal remedy. Antimicrob Agents Chemother 1995;39:2606-2609.
36. Wang LQ, Li Y, Min BS, et al. Cytotoxic mono-tetrahydrofuran ring acetogenins from leaves of Annona montana. Planta Med 2001;67:847-852.
37. Yuan SS, Chang HL, Chen HW, et al. Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase-3-related pathway. Life Sci 2003;72:2853-2861.
38. Chiu HF, Chih TT, Hsian YM, et al. Bullatacin, a potent antitumor Annonaceous acetogenin, induces apoptosis through a reduction of intracellular cAMP and cGMP levels in human hepatoma 2.2.15 cells. Biochem Pharmacol 2003;65:319-327.
39. Chih HW, Chiu HF, Tang KS, et al. Bullatacin, a potent antitumor annonaceous acetogenin, inhibits proliferation of human hepatocarcinoma cell line 2.2.15 by apoptosis induction. Life Sci 2001;69:1321-1331.
40. Zhu XF, Liu ZC, Xie BF, et al. Involvement of caspase-3 activation in squamocin-induced apoptosis in leukemia cell line HL-60. Life Sci 2002;70:1259-1269,
41. Lopez-Lazaro M, Martin-Cordero C, Bermejo A, et al. Cytotoxic compounds from Annonaceus species as DNA topoisomerase I poisons. Anticancer Res 2001;21:3493-3497.
42. Furbacher TR, Gunatilaka AA. Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica. J Nat Prod 2001;64:1294-1296.
43. Mans DR, da Rocha AB, Schwartsmann G, Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist 2000;5:185-198.
44. Rowinsky EK, Noe DA, Ettinger DS, et al. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res 1993;53:1794-1801.
45. Falzon M, McMahon JB, Schuller HM, Boyd MR. Metabolic activation and cytotoxicity of 4-ipomeanol in human non-small cell lung cancer lines. Cancer Res 1986;46:3484-3489.
46. Christian MC, Wittes RE, Leyland-Jones B, et al. 4-lpomeanol: a novel investigational new drug for lung cancer. J Natl Cancer Inst 1989;81:1133-1143.
47. Trela BA, Carlson GP, Turek J, et al. Effect of carbon monoxide on the cytochrome P-450-mediated activation of 4-ipomeanol by the isolated perfused rabbit lung. J Toxicol Environ Health 1989;27:341-350.
48. Boyd MR, Burka LT. In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol. J Pharm Exp Ther 1978;207:687-697.
49. Kasturi VK, Dearing MP, Piscitelli SC, et al. Phase 1 study of a five-day dose schedule of 4-lpomeanol in patients with non-small cell lung cancer. Clin Cancer Res 1998;4:2095-2102.
50. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997;90:270-278.
51. Akimoto M, Miyahara T, Arai J et al. A new delivery system for 5-fluorouracil using prodrug and converting enzyme. Br J Ophthalmol 2002;86:581-586.
52. Pourquier P, Gioffre C, Kohlhagen G, et al. Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase 1. Clin Cancer Res 2002;8:2499-2504.
53. Hoy CA, Rice GC, Kovacs M, Schimke RT. Over-replication of DNA in S phase Chinese hamster ovary cells after DNA synthesis inhibition. J Biol Chem 1987;262:11927-11934.
54. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase 1. J Biol Chem 1985;260:14873-14878.
55. 2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 2002;277:1599-1606.
56. +. Mol Pharmacol 1998;53:846-855.
57. Jean-Claude BJ, Mustafa A, Cetateanu ND, et al. Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro. Br J Cancer 1997;76:467-473.
58. Parsons PG, Carter FB, Morrison L, Regius Mary Sister. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 1981;41:1525-1534.
59. Goodman MF, Lee GM. Adriamycin interactions with T4 DNA polymerase. Two modes of template-mediated inhibition. J Biol Chem 1977;252:2670-2674.
60. Gratzner HG, Fountzilas G, Stein JH, Yunis AA. The assessment of the chemotherapeutic effects of vinca alkaloids by immunofluorescence and flow cytometry. Ann N Y Acad Sci 1986;468:67-79.
61. Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992;187:164-170.
62. Gilbert DM, Neilson A, Miyazawa H, et al. Mimosine arrests DNA synthesis at replication forks by inhibiting deoxyribonucleotide metabolism. J Biol Chem 1995;270:9597-9606.
63. Kimura Y, Okuda H. Effects of naturally occurring stilbene glucosides from medicinal plants and wine, on tumour growth and lung metastasis in Lewis lung carcinoma-bearing mice. J Pharm Pharmacol 2000;52:1287-1295.
64. Gusman J, Malonne H, Atass G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001;22:1111-1117.
65. Kimura Y, Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearins mice. J Nutr 2001;131:1844-1849.
66. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999;1:60-67.
67. Leclerc S, Gamier M, Hoessel R, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimers disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001;276:251-260.
68. Agarwal C, Sharma Y, Zhao J, Agarwal R. A polyphenolic fraction from grape seeds causes irreversible growth inhibition of breast carcinoma MDA-MB468 cells by inhibiting mitogen-activated protein kinases activation and inducing Gl arrest and differentiation. Clin Cancer Res 2000;6:2921-2930.
69. Ye X, Krohn RL, Liu W, et al. The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. Mol Cell Biochem 1999;196:99-108.
70. Bagchi D, Bagchi M, Stohs S, et al. Cellular protection with proanthocyanidins derived from grape seeds. Ann N Y Acad Sci 2002;957:260-270.
71. Tyagi A, Agarwal R, Agarwal C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 2003;22:1302-1316.
72. Barthomeuf C, Debiton E, Mshvildadze V, et al. In vitro activity of hederacolchiside A compared with other saponins from Hedera colchica against proliferation of human carcinoma and melanoma cells. Planta Med 2002;68:672-675.
73. Delmas F, Di Giorgio C, Elias R, et al. Antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro. Planta Med 2000;66:343-347.
74. Kumara SS, Huat BT. Extraction, isolation and characterisation of antitumor principal, alpha-hederin, from the seeds of Nigella sativa. Planta Med 2001;67:29-32.
75. Park HJ, Kwon SH, Lee JH, et al. Kalopanaxsaponin A is a basic saponin structure for the anti-tumor activity of hederagenin monodesmosides. Planta Med 2001;67:118-121.
76. Swamy SM, Huat BT. Intracellular glutathione depletion and reactive oxygen species generation are important in alpha-hederin-induced apoptosis of P388 cells. Mol Cell Biochem 2003;245:127-139.
77. Jeong HG, Choi CY. Expression of inducible nitric oxide synthase by alpha-hederin in macrophages. Planta Med 2002;68:392-396.
78. Kim YK, Yoon SK, Ryu SY. Cytotoxic triterpenes from stem bark of Physocarpus intermedius. Planta Med 2000;66:485-486.
79. Novotny L, Vachalkova A, Biggs D. Ursolic acid: an anti-tumorigenic and chemopreventive activity. Neoplasma 2001;48:241-246.
80. Huang J, Sun Y, Lu S. Experimental study on apoptosis induced by ursolic acid isolated from asparagus in HL-60 cells. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999;19:296-298. [Article in Chinese]
81. Choi BM, Park R, Pae HO, et al. Cyclic adenosine monophosphate inhibits ursolic acid-induced apoptosis via activation of protein kinase A in human leukaemic HL-60 cells. Pharmacol Toxicol 2000;86:53-58.
82. Back JH, Lee YS, Kang CM, et al. Intracellular Ca2+ release mediates ursolic acid-induced apoptosis in human leukemic HL-60 cells. Int J Cancer 1997;73:725-728.
83. Lauthier F, Taillet L, Trouillas P, et al. Ursolic acid triggers calcium-dependent apoptosis in human Daudi cells. Anticancer Drugs 2000;11:737-745.
84. Hollosy F, Idei M, Csorba G, et al. Activation of caspase-3 protease during the process of ursolic acid and its derivative-induced apoptosis. Anticancer Res 2001;21:3485-3491.
85. Kim DK, Back JH, Kang CM, et al. Apoptotic activity of ursolic acid may correlate with the inhibition of initiation of DNA replication. Int J Cancer 2000;87:629-636.
86. Neto CC, Vaisberg AJ, Zhou BN, et al. Cytotoxic triterpene acids from the Peruvian medicinal plant Polylepis racemosa. Planta Med 2000;66:483-484.
87. Choi YH, Baek JH, Yoo MA, et al. Induction of apoptosis by ursolic acid through activation of caspases and down-regulation of c-IAPs in human prostate epithelial cells. Int J Oncol 2000;17:565-571.
88. Kim SH, Ahn BZ, Ryu SY. Antitumour effects of ursolic acid isolated from Oldenlandia diffusa. Phytother Res 1998;12:553-556.
89. Sadava D, Ahn J, Zhan M, et al. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemother Pharmacol 2002;49:261-266.
90. Shan BE, Zhang JY, Du XN. Immunomodulatory activity and anti-tumor activity of Oldenlandia diffusa in vitro. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001;21:370-374. [Article in Chinese]
91. Shan B E, Yoshida Y, Sugiura T, Yamashita U. Stimulating activity of Chinese medicinal herbs on human lymphocytes in vitro. Int J Immunopharmacol 1999;21:149-159.
92. Yoshida Y, Wang MQ, Liu JN, et al. Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol 1997;19:359-370.
93. Chung HS, Jeong HJ, Hong SH, et al. Induction of nitric oxide synthase by Oldenlandia diffusa in mouse peritoneal macrophages. Biol Pharm Bull 2002;25:1142-1146.
94. Pessoa C, Silveira ER, Lemos TL, et al. Antiproliferative effects of compounds derived from plants of Northeast Brazil. Phytother Res 2000;14:187-191.
95. Carchman RA, Harris LS, Munson AE. The inhibition of DNA synthesis by cannabinoids. Cancer Res 1976;36:95-100.
96. Baumann B, Bohnenstengel F, Siegmund D, et al. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J Biol Chem 2002;277:44791-44800.
97. Chaidir HJ, Nugroho BW, Bohnenstengel FI, et al. New insecticidal rocaglamide derivatives from flowers of Aglaia duperreana (Meliaceae). Phytochemistry 1999;52:837-842.
98. Lee SK, Cui B, Mehta RR, et al. Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem Biol Interact 1998;115:215-228.
99. Kinghorn AD, Farnsworth NR, Soejarto DD, et al. Novel strategies for the discovery of plant derived anticancer agents. Pure Appl Chem 1999;71:1611-1618.
100. Wang SK, Duh CY. Cytotoxic cyclopenta[b]benzofuran derivatives from the stem bark of Aqlaici formosana. Planta Med 2001;67:555-557.
101. Ohse T, Ohba S, Yamamoto T, et al. Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata. J Nat Prod 1996;59:650-652.
102. Bohnenstengel FI, Steube KG, Meyer C, et al. 1H-cyclopenta[b]benzofuran lignans from Aglaia species inhibit cell proliferation and alter cell cycle distribution in human monocytic leukemia cell lines. Z Naturforsch [C] 1999;54:1075-1083.
103. Olsnes S, Stirpe F, Sandvig K, Pihl A. Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem 1982;257:13263-13270.
104. Zarkovic N, Vukovic T, Loncaric I, et al. An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm 2001;16:55-62.
105. Lavelle EC, Grant G, Pusztai A, et al. Mistle-toe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2. Immunology 2002;107:268-274.
106. Bantel H, Engels IH, Voelter W, et al. Mistle-toe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res 1999;59:2083-2090.
107. Maier G, Fiebig HH. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 2002;13:373-379.
108. Lavastre V, Pelletier M, Sailer R, et al. Mechanisms involved in spontaneous and Viscum album agglutinin-I-induced human neutrophil apoptosis: Viscum album agglutinin-I accelerates the loss of antiapoptotic Mcl-1 expression and the degradation of cytoskeletal paxillin and vimentin proteins via caspases. J Immunol 2002;168:1419-1427.
109. Boneberg EM, Hartung T. Mistletoe lectin-1 increases tumor necrosis factor-alpha release in lipopolysaccharide-stimulated whole blood via inhibition of interleukin-10 production. J Pharmacol Exp Ther 2001;298:996-1000.
110. Siegle I, Fritz P, McClellan M, et al. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res 2001;21:2687-2691.
111. Hohmann J, Forgo P, Molnar J, et al. Antiproliferative Amaryllidaceae alkaloids isolated from the bulbs of Sprekelia formosissima and Hymenocallis festalis. Planta Med 2002;68:454-457.
112. Min BS, Gao JJ, Nakamura N, et al. Cytotoxic alkaloids and a flavan from the bulbs of Crinum asiaticum var. japonicuin. Chem Pharm Bull (Tokyo) 2001;49:1217-1219.
113. Tram N, Zvetkova E, Nikolova E, et al. A novel in vitro and in vivo T-lymphocyte activating factor in Crinum latifolium (L.) aqueous extracts. Exp Pathol Parasitol 1999;3:21-26.
114. Vrijsenz R, Berghep DA, Vlietinckg AJ, Boeyet A. Lycorine: a eukaryotic termination inhibitor? J Biol Chem 1986;261:505-507.
115. Alexandrova R, Alexandrov I, Velcheva M, Varadinova T. Phytoproducts and cancer. Exp Pathol Parasitol 2000;4:15-26.
116. Wilkoff LJ, Dulmadge EA, Vasanthakumar G, Donahue JP. Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharrinatonine. Cancer Chemother Pharmacol 1993;33:149-153.
117. Efferth T, Sauerbrey A, Halatsch ME, et al. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch Pharmacol 2003;367:56-67.
118. Lee SK, Nam KA, Heo YH. Cytotoxic activity and G2/M cell cycle arrest mediated by antofine, a phenanthroindolizidine alkaloid isolated from Cynanchum paniculatum. Planta Med 2003;69:21-25.
119. Carrasco L, Jimenez A, Vazquez D. Specific inhibition of translocation by tubulosine in eukaryotic polysomes. Eur J Biochem 1976;64:1-5.
120. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4-27.
121. Tang W, Hemm I, Bertram B. Recent development of antitumor agents from Chinese herbal medicines. Part II. High molecular compounds(3). Planta Med 2003;69:193-201.
122. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 1993;13:1815-1820.
123. Kodama N, Komuta K, Nanba H. Can maitake MD-fraction aid cancer patients? Altern Med Rev 2002;7:236-239.
124. Wong BC, Wang WP, Cho CH, et al. 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis 2001;22:1349-1354.
125. Tong WG, Ding XZ, Witt RC, Adrian TE. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 2002;1:929-935.
126. Tong WG, Ding XZ, Adrian TE. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 2002;296:942-948.
127. Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 2002;62:2721-2727.
128. Matsuzaki Y, Kurokawa N, Terai S, et al. Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn J Cancer Res 1996;87:170-177.
129. Austin CA, Patel S, Ono K, et al. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J 1992;282:883-889.
130. Wartenberg M, Budde P, De Marees M, et al. Inhibition of tumor-induced angiogenesis and matrix-metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional Chinese medicine. Lab Invest 2003;83:87-98.
131. Chen YC, Shen SC, Lee WR, et al. Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 2002;76:351-359.
132. Lee WR, Shen SC, Lin HY, et al. Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca(2+)-dependent endonuclease. Biochem Pharmacol 2002;63:225-236.
133. Linde K, ter Riet G, Hondras M, et al. Systematic reviews of complementary therapies - an annotated bibliography. Part 2: Herbal medicine. BMC Complement Altern Med 2001;1:5.